Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Stopped The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.

Conditions

• Non-Small Cell Lung Cancer
• Multiple Myeloma

Interventions

• BIOLOGICAL: Tecemotide
• OTHER: No intervention

Sponsor

Merck KGaA, Darmstadt, Germany